Abstract
Guideline overview
This guideline is developed as a part of the BE-SAFE project, funded by the European Union's Horizon Europe research and innovation programme and the Swiss State Secretariat for Education, Research and Innovation (SERI)[1]. The overarching goal of BE-SAFE is to improve patient safety by addressing knowledge and practice gaps related to the reduction of Benzodiazepines and Sedative-Hypnotics (BSHs) used for sleep difficulties in Europe. The present recommendations are part of several clinical practice guidelines produced within the second work package of BE-SAFE, specifically on strategies for implementing discontinuation and deprescription of BSHs in patients diagnosed with insomnia disorder.
This guideline is developed as a part of the BE-SAFE project, funded by the European Union's Horizon Europe research and innovation programme and the Swiss State Secretariat for Education, Research and Innovation (SERI)[1]. The overarching goal of BE-SAFE is to improve patient safety by addressing knowledge and practice gaps related to the reduction of Benzodiazepines and Sedative-Hypnotics (BSHs) used for sleep difficulties in Europe. The present recommendations are part of several clinical practice guidelines produced within the second work package of BE-SAFE, specifically on strategies for implementing discontinuation and deprescription of BSHs in patients diagnosed with insomnia disorder.
| Original language | English |
|---|---|
| Type | Clinical practice guideline |
| Media of output | Electronic |
| Publication status | Published - 30 Aug 2023 |
Fingerprint
Dive into the research topics of 'BE-SAFE: Deprescription of benzodiazepine and sedative hypnotics (BSHs) in insomnia disorder: Clinical practice guidelines'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver